Arama

EISSN 2148-5607

TJG IS INDEXED IN SCI-EXPANDED AND PUBMED IMPACT FACTOR: 1.4

Turkish Journal of Gastroenterology

PDF

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

All Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 9 results

Ranking

Release Date Sort Sort Article Type

Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma

(Turk J Gastroenterol 2010; 21: 197-198) DOI: 10.4318/tjg.2010.0087

Abstract Full Text ( PDF) Related Articles

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Bilgehan Aygen, Ahmet Muzaffer Demir, Mahmut Gümüş, Oğuz Karabay, Sabahattin Kaymakoğlu, Aydın Şeref Köksal, İftihar Köksal, Necati Örmeci, Fehmi Tabak

(Turk J Gastroenterol 2018; 29: 259-269) DOI: 10.5152/tjg.2018.18263

Abstract Full Text ( PDF) Related Articles

Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity

Aslı Haykır Solay, Ali Acar, Fatma Eser, Ferit Kuşcu, Emin Ediz Tütüncü, Gülnur Kul, Gönül Çiçek Şentürk, Yunus Gürbüz

(Turk J Gastroenterol 2018; 29: 561-565) DOI: 10.5152/tjg.2018.18032

Abstract Full Text ( PDF) Related Articles

Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity

Evaluation of rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive treatment

Hepatitis b reactivation rate in patients using anti tnf theraphy: Evaluation of patients not received anti viral prophylaxis

Prospective and Randomized Comparison of Tenofovir and Entecavir in Hepatitis B Reactivation Prophylaxis in Patients Receiving Immunosuppressive Therapy

Comparison of antivirals in prophylaxis of HBV reactivation in patients receiving immunsuppressive therapy

Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection

Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients